JP2016104790A5 - - Google Patents

Download PDF

Info

Publication number
JP2016104790A5
JP2016104790A5 JP2016006778A JP2016006778A JP2016104790A5 JP 2016104790 A5 JP2016104790 A5 JP 2016104790A5 JP 2016006778 A JP2016006778 A JP 2016006778A JP 2016006778 A JP2016006778 A JP 2016006778A JP 2016104790 A5 JP2016104790 A5 JP 2016104790A5
Authority
JP
Japan
Prior art keywords
protein
vector
tissue
dna encoding
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2016006778A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016104790A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2016104790A publication Critical patent/JP2016104790A/ja
Publication of JP2016104790A5 publication Critical patent/JP2016104790A5/ja
Ceased legal-status Critical Current

Links

JP2016006778A 2008-04-30 2016-01-18 損傷組織の機能的再生促進医薬 Ceased JP2016104790A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2008119324 2008-04-30
JP2008119324 2008-04-30

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2014019961A Division JP5960735B2 (ja) 2008-04-30 2014-02-05 損傷組織の機能的再生促進医薬

Publications (2)

Publication Number Publication Date
JP2016104790A JP2016104790A (ja) 2016-06-09
JP2016104790A5 true JP2016104790A5 (enExample) 2016-07-21

Family

ID=41255155

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2010510169A Expired - Fee Related JP5814549B2 (ja) 2008-04-30 2009-04-30 損傷組織の機能的再生促進医薬
JP2014019961A Active JP5960735B2 (ja) 2008-04-30 2014-02-05 損傷組織の機能的再生促進医薬
JP2016006778A Ceased JP2016104790A (ja) 2008-04-30 2016-01-18 損傷組織の機能的再生促進医薬

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2010510169A Expired - Fee Related JP5814549B2 (ja) 2008-04-30 2009-04-30 損傷組織の機能的再生促進医薬
JP2014019961A Active JP5960735B2 (ja) 2008-04-30 2014-02-05 損傷組織の機能的再生促進医薬

Country Status (10)

Country Link
US (1) US20110097309A1 (enExample)
EP (1) EP2301560A4 (enExample)
JP (3) JP5814549B2 (enExample)
KR (1) KR20110027665A (enExample)
CN (1) CN102076351A (enExample)
AU (1) AU2009240885A1 (enExample)
BR (1) BRPI0911436A2 (enExample)
CA (1) CA2722906A1 (enExample)
RU (1) RU2010148785A (enExample)
WO (1) WO2009133940A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009240885A1 (en) * 2008-04-30 2009-11-05 Genomix Co., Ltd. Pharmaceutical agent for promoting the functional regeneration of damaged tissue
WO2009133939A1 (ja) * 2008-04-30 2009-11-05 株式会社ジェノミックス 末梢循環への骨髄由来多能性幹細胞動員薬
KR20110017371A (ko) 2008-04-30 2011-02-21 가부시키가이샤 제노믹스 생체내 기능적 세포의 고효율 채취법
KR20120135190A (ko) 2009-10-28 2012-12-12 고꾸리쯔 다이가꾸 호우징 오사까 다이가꾸 골수 간엽계 및/또는 다능성 줄기세포의 혈중 동원(動員)에 의한 조직 재생 촉진제
JP5852773B2 (ja) * 2010-06-01 2016-02-03 ピアス株式会社 骨髄間葉系幹細胞の誘引剤の製造方法、骨髄間葉系幹細胞の誘引方法、及び、骨髄間葉系幹細胞の誘引剤を製造するための使用
CN103687946B (zh) 2011-04-26 2017-05-03 吉诺米克斯股份有限公司 用于诱导组织再生的肽及其应用
PL2913058T3 (pl) 2012-10-25 2018-04-30 Genomix Co., Ltd. Nowy sposób leczenia zawału mięśnia sercowego przy użyciu fragmentu HMGB1
CN104955470B (zh) * 2012-10-25 2017-06-16 吉诺米克斯股份有限公司 利用了hmgb1片段的针对脊髄损伤的新型治疗方法
EP3349793B1 (en) * 2015-09-14 2021-08-11 Université Laval Anti-s100a8 for treating leukemia
BR112019014921A2 (pt) 2017-01-27 2020-03-31 StemRIM Inc. Agente terapêutico para miocardiopatia, infarto antigo do miocárdio e insuficiência cardíaca crônica
CA3059544A1 (en) 2017-04-25 2018-11-01 Shionogi & Co., Ltd. Peptide for inducing regeneration of tissue, and use thereof
CN110709506A (zh) * 2017-07-18 2020-01-17 株式会社资生堂 间充质干细胞导引剂
JPWO2019107530A1 (ja) 2017-12-01 2020-11-26 株式会社ステムリム 炎症性腸疾患の治療薬
US12421498B2 (en) 2017-12-01 2025-09-23 StemRIM Inc. Ectodermal mesenchymal stem cells and method for producing same
WO2019156137A1 (ja) 2018-02-08 2019-08-15 株式会社ステムリム 乾癬の治療薬
US12304933B2 (en) * 2018-10-05 2025-05-20 StemRIM Inc. Disease treatment drug based on mesenchymal-stem-cell mobilization
EP3756679A1 (en) * 2019-06-28 2020-12-30 Université de Genève Compositions for use in the treatment of insulin deficiency conditions
CN111494423B (zh) * 2020-04-22 2022-01-25 上海市东方医院（同济大学附属东方医院） 一种干细胞组合物及其应用和干细胞滴液
CN115058388A (zh) * 2022-03-14 2022-09-16 福建医科大学附属协和医院 间充质干细胞创面修复优势功能亚群及其鉴定和应用
CN120837666B (zh) * 2025-09-22 2026-02-10 中国人民解放军军事科学院军事医学研究院 靶向巨噬细胞s100a9蛋白在肝纤维化治疗中的应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5658894A (en) * 1989-04-23 1997-08-19 The Trustees Of The University Of Pennsylvania Compositions for inhibiting restenosis
JP3018313B2 (ja) * 1996-02-23 2000-03-13 雪印乳業株式会社 骨形成促進及び骨吸収防止剤
EP1114862A3 (de) * 1999-11-17 2003-08-06 Switch Biotech Aktiengesellschaft Verwendung von Polypeptiden oder diese kodierende Nukleinsäuren zur Diagnose oder Behandlung von Hauterkrankungen sowie ihre Verwendung zur Identifizierung von pharmakologisch aktiven Substanzen
AU4328801A (en) * 2000-02-24 2001-09-03 Xcyte Therapies Inc Simultaneous stimulation and concentration of cells
US20040191246A1 (en) * 2003-02-26 2004-09-30 Connelly Patrick R. Process for in vivo treatment of specific biological targets in bodily fluid
EP1390058A2 (en) * 2001-04-30 2004-02-25 Switch Biotech Aktiengesellschaft Mrp8/mrp14 heterodimer, or its individual components in combination, for treating and/or preventing skin diseases, wounds and/or wound-healing disturbances
DE10121254A1 (de) * 2001-04-30 2002-11-07 Switch Biotech Ag MRP8/MRP14 Heterodimers oder seiner Einzelkomponenten alleine oder in Kombination zur Behandlung und/oder Prävention von Hauterkrankungen, Wunden und/oder Wundheilungsstörungen, die durch eine verringerte Menge an MRP8/MRP14 Heterodimeren gekennzeichnet sind
EP1402068A4 (en) * 2001-05-09 2006-07-12 Univ Cleveland Hospitals EVALUATION OF SKIN DAMAGE CAUSED BY ULTRAVIOLET RAYS USING NEW GENE MARKERS, METHODS AND COMPOSITIONS THEREOF
US7220723B2 (en) * 2001-05-15 2007-05-22 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
ITMI20011986A1 (it) * 2001-09-25 2003-03-25 San Raffaele Centro Fond Metodo e composizione per l'attivazione di cellule presentanti l'antigene
US20040265971A1 (en) * 2001-11-19 2004-12-30 Hidetaka Sato Drug mobilizing pluripotent stem cells from tissue into peripheral blood
JP2005537253A (ja) * 2002-07-03 2005-12-08 フォンダッチォーネ・セントロ・サン・ラファエル・デル・モンテ・タボール 組織損傷の治療におけるおよび／または組織修復を促進するためのｈｍｇｂ１の使用
DE60327075D1 (de) * 2002-07-05 2009-05-20 Univ Laval Der entzündungsreaktionen
GB0226251D0 (en) * 2002-11-11 2002-12-18 San Raffaele Centro Fond Acetylated protein
EP1579221A2 (de) * 2003-01-03 2005-09-28 Alcedo Biotech GmbH Verwendungen von hmgb, hmgn, hmga proteinen
DE602004017148D1 (de) * 2003-03-28 2008-11-27 Univ Laval S100 protein als aktivator neutrophiler zellen zur verminderung der neutropenie bei der krebsbehandlung
CA2574548A1 (en) * 2004-07-20 2006-01-26 Fondazione Centro San Raffaele Del Monte Tabor Use of hmgb1 for wound healing
KR100593397B1 (ko) * 2004-10-27 2006-06-28 한국원자력연구소 중배엽 줄기세포 및/또는 ｐ 물질을 함유하는 상처 치유또는 상처 치유 촉진제, 또는 세포 치료제
WO2006047820A1 (en) * 2004-11-01 2006-05-11 Newsouth Innovations Pty Limited Use of calgranulin a and b in the promotion and inhibition of mineralized tissue formation
AU2007315073A1 (en) * 2006-10-30 2008-05-08 Genomix Co., Ltd. Pharmaceuticals that promote functional regeneration of damaged tissues
AU2009240885A1 (en) * 2008-04-30 2009-11-05 Genomix Co., Ltd. Pharmaceutical agent for promoting the functional regeneration of damaged tissue
KR20110017371A (ko) * 2008-04-30 2011-02-21 가부시키가이샤 제노믹스 생체내 기능적 세포의 고효율 채취법
WO2009133939A1 (ja) * 2008-04-30 2009-11-05 株式会社ジェノミックス 末梢循環への骨髄由来多能性幹細胞動員薬

Similar Documents

Publication Publication Date Title
JP2016104790A5 (enExample)
PH12017502424A1 (en) Modified factor ix, and compositions, methods and uses for gene transfer to cells, organs and tissues
PH12020551317A1 (en) Anti-cd73 antibodies and methods of use thereof
PH12019500709A1 (en) Anti-lag-3 antibodies and methods of use thereof
WO2018191502A3 (en) Anti-cd137 antibodies and methods of use thereof
PH12018502400A1 (en) Anti-tim-3 antibodies and methods of use thereof
EP4289484A3 (en) Anti-ctla-4 antibodies and methods of use thereof
MX2021006615A (es) Proteinas de union triespecificas y metodos de uso.
EA201992609A1 (ru) Слитые белки, содержащие интерлейкин-2, и их применения
JP2016514956A5 (enExample)
BR112016029318A2 (pt) tratamento de mielomas
WO2016046778A3 (en) Protease-activatable bispecific proteins
WO2015197598A3 (en) Multispecific antigen binding proteins
WO2015109124A3 (en) Immunomodulatory agents
MX2018007145A (es) Anticuerpos antimiostatina, polipeptidos que contienen regiones de fragmento cristalizable (fc) variantes y metodos de uso.
WO2016207273A3 (en) Multispecific antigen binding proteins
CY1115502T1 (el) Παραγοντες διεγερσης αποπτωσης για τη θεραπεια καρκινου και ανοσων και αυτοανοσων ασθενειων
JOP20220079A1 (ar) بروتين ربط متعددة الخصوصية لمعالجة السرطان
PH12018502593A1 (en) Combinations of linagliptin and metformin
MX2019013587A (es) Proteinas agonistas del receptor del ligando que induce la apoptosis relacionada con el factor de necrosis de tumor de cadena individual.
UA117045C2 (uk) Гібридний білок для пригнічення ангіогенезу або судинного росту та його застосування
PH12020550483A1 (en) Anti-apoc3 antibodies and methods of use thereof
SG10201805646WA (en) Angiopoietin-like 4 antibodies and methods of use
EA202091567A1 (ru) Химерные белки мти
WO2016020882A3 (en) Angiopoetin-like 4 (angptl4) antibodies and methods of use